La vendita allo scoperto per Helix BioPharma dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Helix BioPharma. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Helix BioPharma (OTC:HBPCF) Azioni, Report sulle vendite allo scoperto

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.

HELIX BIOPHARMA CORP by Helix Biopharma Corp.

Helix BioPharma Corp

Needham analyst James Ricchiuti maintains Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) with a Buy and raises the price target from $24 to $26.

News

Price Target

Analyst Ratings

FARO

Needham Maintains Buy on Faro Technologies, Raises Price Target to $26

STLA

Infineon And Stellantis Partner To Develop Advanced Power Architecture For Next-Gen EVs, Signing Agreements For PROFET Power Switches And SiC Semiconductors To Enhance Efficiency, Range, And Cost-Effectiveness

WIIM

ENSC

Ensysce Biosciences shares are trading higher after the company announced it received notice that it may continue its listing on the Nasdaq capital market.

Biotech

General

LUCD

Lucid Diagnostics' ESOGUARD BE-1 Clinical Validation Study On EsoGuard Precancer Testing Accepted For Publication, Strengthening Medicare Coverage Submission

<a href="https://www.globenewswire.com/Tracker?data=K9SmH7B1_SDtsVM1A3P23w1LcKudUCuIB3vnQy38UOAk3Gj9JsL8hzInANndAgVYgjRjMi-zc-tVAp5oOf50JVJts-ACvqZ5766e8yT_iprwdSuSgDKQGF3g9Bcacrh4">Duos Technologies Group, Inc.</a> ("Duos" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOT#NASDAQ">DUOT</a>), through its operating subsidiary <a href="https://www.globenewswire.com/Tracker?data=K9SmH7B1_SDtsVM1A3P23x9C9k0LKy70oTFz_7GBphPDNlDdgapIkFBdAEQPE7DZL1g_hMfqoul3MfoVgyHuzQ==">Duos Edge AI, Inc</a>. ("Duos Edge AI"), a provider of adaptive, versatile, and streamlined Edge Data Center ("EDC") solutions tailored to meet evolving needs in any environment, announced the early deployment of three new EDCs across Texas. The accelerated acquisition was enabled by using a financing partner, underscoring the Company's fast-to-market capabilities in delivering edge computing solutions for underserved areas. These additional EDCs will provide low-latency, high-speed internet access tailored for remote districts, directly addressing connectivity challenges faced by schools and public institutions in Texas. The acquisition of these additional units aligns with Duos Edge AI's commitment to supporting regional development by enabling seamless access to modern digital resources.

DUOT

Duos Edge AI Acquires Additional Edge Data Centers; No Financial Terms Disclosed

CDLX

Cardlytics shares are trading lower. The company reported Q3 financial results.

SWKS

Skyworks Secures IATF 16949 Certification Across Multiple Facilities, Showcasing Automotive Telematics Portfolio At Electronica 2024

Earnings

LBRDA

LBRDK

Liberty Broadband Q3 Sales $262M vs $245M Estimate

Goldman Sachs analyst Neil Mehta downgrades Atlas Energy Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AESI#NYSE">AESI</a>) from Buy to Neutral and announces $21 price target.

Downgrades

AESI

Goldman Sachs Downgrades Atlas Energy Solutions to Neutral, Announces $21 Price Target

Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.64) by 32.81 percent. This is a 88.89 percent decrease over losses of $(0.45) per share from the same period last year.

Earnings Misses

VERA

Vera Therapeutics Q3 EPS $(0.85) Misses $(0.64) Estimate

PMV Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMVP#NASDAQ">PMVP</a>) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.35) by 5.71 percent. This is a 8.82 percent decrease over losses of $(0.34) per share from the same period last year.

PMVP

PMV Pharma Q3 EPS $(0.37) Misses $(0.35) Estimate

Cyngn shares are trading higher after the company reported better-than-expected Q3 EPS results and announced the progress of its proprietary computer vision technology for industrial autonomous machines built on Nvidia accelerated computing.

NeuroBo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRBO#NASDAQ">NRBO</a>) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.73) by 24.66 percent.

Earnings Beats

NRBO

NeuroBo Pharmaceuticals Q3 2024 GAAP EPS $(0.55) Beats $(0.73) Estimate

Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith downgrades Lemonade (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) from Market Perform to Underperform and raises the price target from $18 to $21.

LMND

Keefe, Bruyette & Woods Downgrades Lemonade to Underperform, Raises Price Target to $21

<ul>
<li>Celularity Raises Full Year 2024 Expected Net Sales Guidance to $54 Million to $60 Million, Compared to Previous Guidance of $50 Million to $56 Million</li>
<li>October Expected Net Sales of $8.3 Million to $8.9 Million Marks the Highest Single-Month Figure in its History &nbsp;</li>
<li>Celularity Filed its Second Quarter Form 10-Q and is Now Current With its Quarterly Report Filings &nbsp;</li>
</ul>
FLORHAM PARK, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) ("Celularity") a regenerative and cellular medicine company, today announced that it has increased expected net sales guidance for the full year 2024 to $54 million to $60 million, up from $50 million to $56 million previously announced in February. The increased guidance is based on higher expected net sales through October of its advanced biomaterial products. Expected net sales for full year 2024 consist of $49 million to $54.5 million sales of advanced biomaterial products and $5.0 million to $5.5 million net sales of biobanking services. For the full year 2024, Celularity now expects net sales of its advanced biomaterial products to grow by 180% to 212% over the prior year.
October expected net sales were $8.3 million to $8.9 million, marking Celularity's highest-ever single-month expected net sales. For the ten months ending October 31, 2024, expected net sales were $44.4 million, consisting of advanced biomaterial product sales of $40.2 million and biobanking sales of $4.2 million, and includes approximately $9 million in expected net sales of Celularity's new Rebound&#x2122; product. Rebound adds to Celularity's portfolio of placental-derived advanced biomaterial products, sales of which through the first half of 2024 exceeded $24 million, which is greater than Celularity's full-year sales in 2023.

Guidance

CELU

Celularity Raises FY24 Expected Net Sales Guidance From $50M-$56M To $54M-$60M

&nbsp;<a href="https://www.globenewswire.com/Tracker?data=jbGNeQmd_-SEIEkEILARBXOiWYhKHpHnzQDdQMP72ixYJYilGMg-tnExpp9w5y0hPdB7R5RJQ6_MkaLVCbFGjg==">Genasys</a> Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNSS#NASDAQ">GNSS</a>), the global leader in <a href="https://www.globenewswire.com/Tracker?data=U0QiCniEk1ZGuiVmDMaQ-jQj513AbFB98zgb2I_6MiJJ5n1AZpYutncFewIwZT4I640uFSFPf_t5zZcyqfHjGQl0C7QVP9YuxXNn5f7Fs8m1nRyigmzM4TUpx-E5pFeF">Protective Communications</a>, today announced a four-year contract with Los Angeles County (LA County) for <a href="https://www.globenewswire.com/Tracker?data=jbGNeQmd_-SEIEkEILARBXqK_W_YzmVZYZf3xpi-OIpIS0IMmYtE4d62Y1d82HSJxAQHBpZNoO2CBFh0OGwXPL9bVRL7AuiWbOTtT7d1gwM=">Genasys ALERT</a> (ALERT) mass notification software services. <a href="https://www.globenewswire.com/Tracker?data=jmjvTg1b7PUmBQnXAtcXKLoFTdSq0v5oe-LqEvdCTQnIXm22peJ3stWWy8Auc6GAsomjc5zaQG00GlOEIPHuCMEpfVro7c6sX1kWrPGJDEW2frG24N7SlpMXJZ7gL6gJqei8FupNFq_r4XljhCUCxt8Wl6lrmNextfElgrwqpk1RJ6PYogxCL1Zay7LsZW4n1wrfXDlDwJdT4fGioRfPV11p26V-Qe12AeDtY4B0wpu_YRQ_EAY1r2h2fy3WzxAC">LA County's successful use of Genasys EVAC</a> (EVAC) emergency evacuation management services <a href="https://www.globenewswire.com/Tracker?data=tcaKAUng9tRbXF3D2PMUka3qv4AbHMc55bSDRkIDuO3C2OpyqxXOSu7Qpi4Nt4cEA-XRXDtmwYTaV4dWsqrz87-hQ_M--LPJU130EAai6i_F-5FgygDoOXK-KJbAIT9cjf7GwxdHXXeJzAKre_fKCXVuisVmLDuSFc4_SpkPkbb9VOEcCJ7ZyCTBOqCVTf4y">since 2022</a> led to the County's decision to replace its previous mass notification provider with ALERT to enhance public safety for the county's 9.8 million residents and 50 million annual visitors during wildfires and other disasters.

GNSS

Los Angeles County Adds Genasys ALERT Emergency Warning And Notification To Genasys EVAC Emergency Management And Planning

COHR

Coherent shares are trading better after the company reported better-than-expected Q1 financial results.

Edgewise Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.37) by 2.7 percent. This is a 12.2 percent increase over losses of $(0.41) per share from the same period last year.

EWTX

Edgewise Therapeutics Q3 EPS $(0.36) Beats $(0.37) Estimate

Vistra shares are trading higher after the company reported better-than-expected Q3 sales results.

WK Kellogg shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results and raised its FY24 adjusted EBITDA guidance.

Helix Biopharma GAAP EPS of -$0.01

HBPCF

Helix BioPharma

Comments

Helix BioPharma

Vendite allo scoperto

Helix BioPharma (OTC:HBPCF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO